THE PELLETTLABORATORYRESEARCH ASSOCIATEFu-Zhang Wang, Ph.D.POSTDOCTORAL FELLOWSSubhendu Das, Ph.D.Olena Skomorovska-Prokvolit, Ph.D.SENIOR RESEARCHTECHNOLOGISTGeorge CompitelloCOLLABORATORSVIROLOGYRobin Avery, M.D. 1Belinda Yen-Liberman, Ph.D. 21Dept. of Infectious Diseases,CCF2Dept. of Pathology andLaboratory Medicine, CCFHerpesviruses: Molecular Marvelsand Potent PathogensHerpesviruses constitute a virus family ofgreat genetic and biologic diversity. Theherpesviruses that infect humans includeherpes simplex virus types 1 and 2 (whichpredominantly cause oral and genital disease,respectively), the virus that causes chicken poxand shingles (varicella-zoster virus), most casesof infectious mononucleosis (Epstein-Barrvirus), roseola infantum (Human herpesvirus 6B),and Kaposi’s sarcoma (Kaposi’s sarcomaassociatedherpesvirus, a.k.a. Human herpesvirus8). Of the human herpesviruses,the one with perhapsthe greatest clinical impact ishuman cytomegalovirus,which is a leading cause ofcongenitally acquired mentalretardation and deafness,causes some infectiousmononucleosis, is a majorpathogen in immunocompromisedpatients, and mayhave a role in the developmentof atherosclerosis andother occlusive vasculardiseases. An importantshared biologic property ofall herpesviruses is latency,the process by which theseviruses persist in their host ina generally quiescent mannerfor the life of the host. Inimmunocompromised hosts,such as organ transplant recipients who havebeen chemically immunosuppressed to preventrejection of the transplanted organ, theseformerly quiescent viruses can each emerge fromlatency and cause significant disease that is oftendifficult to treat.The genetic complexity and diversity ofCannon, M.J., Dollard, S.C., Smith, D.K., Klein, R.S., Schuman, P., Rich, J.D., Vlahov,D., Pellett, P.E. for the HIV Epidemiology <strong>Research</strong> Study Group (2001) Blood-borne andsexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiencyvirus infection. N. Engl. J. Med. 344:637-643.Krug, L.T., Inoue, N., and P.E. Pellett (2001) Sequence requirements for interaction of humanherpesvirus 7 origin binding protein with the origin of lytic replication. J. Virol. 75:3925-3936.Cannon, M.J., Dollard, S.C., Black, J.B., Edlin, B.R., Hannah, C., Hogan, S.E., Patel,M.M., Jaffe, H.W., Offermann, M.K., Spira, T.J., Pellett, P.E., and C.J. Gunthel (<strong>2003</strong>)Risk factors for Kaposi’s sarcoma in men seropositive for both Human herpesvirus 8 andhuman immunodeficiency virus. AIDS 17:215-222.Stover, C.T., Smith, D.K., Schmid, D.S., Pellett, P.E., Stewart, J.A., Klein, R.S., Mayer,K., Vlahov, D., Schuman, , P. and M.J. Cannon, for the HIV Epidemiology <strong>Research</strong>Study Group (<strong>2003</strong>) Prevalence of and risk factors for viral infections among HIV-infectedand high-risk-uninfected women. J. Infect. Dis. 187:1388-1396.Cannon, M.J., Laney, A.S., and P.E. Pellett (<strong>2003</strong>) Human herpesvirus 8: current issues.Clin. Infect. Dis. 37:82-87.The Department of Molecular BiologyPhilip E. Pellett, Ph.D.herpesviruses, coupled with their complex hostbiology, make these viruses engaging objects ofscientific study, providing fascinating and importantintersections with almost every area ofmolecular biology, cellular biology, immunology,pathogenesis, and epidemiology.The purposes of this laboratory (establishedin <strong>2003</strong>) are (i) to conduct basic researchthat adds to our fundamental understanding ofthe relationships among the various herpesviruses,the processes by which human herpesvirusesreplicate and persist inpopulations on an evolutionarytime scale, and themechanisms by which theseviruses cause disease, and (ii)to use this knowledge toprevent or treat herpesvirusassociateddisease.Initiation of HerpesvirusDNA ReplicationOur studies ofherpesvirus replicationinclude structure-functionanalysis of the origin-bindingprotein (OBP), a protein thatis con-served among manymembers of the herpesvirusfamily. OBP binds to theorigin of lytic replication andserves as a nucleatingscaffold for assem-bly of thereplication fork and as an active parti-cipant inpreparing the origin sequence for repli-cationinitiation. We have mapped the structuraldomains responsible for the sequence-specificDNA binding activity of OBP, defined sequencesit can bind to, and found that the protein interactswith one face of the DNA double helix. In subsequentwork, we will identify important conservedfeatures of the structure of the proteinand identify means by which the protein-DNAinteraction can be blocked, so as to inhibit viralreplication.Human Cytomegalovirus Molecular andCellular BiologyWe are initiating a research programdirected at understanding the role of humancytomegalovirus in disease processes, such asinflammation and immune diversion, and themanner in which certain virally encoded proteinsand viral genetic variation contribute to this.Herpesvirus Translational <strong>Research</strong>The translational research component of ourprogram is directed at improving patient out-comeswith respect to herpesvirus-related disease. Thiseffort will involve a multidisciplinary collaborationbetween basic laboratory scientists, clinical virologists,infectious and vascular disease specialists,epidemiologists, and biostatisticians.114
The AIDS pandemic has been recognizedas one of the most important healththreats of the coming century. Therapeuticinterventions, host immuneresponse, and vacci-nations haveall failed to control the humanimmunodeficiency virus (HIV)epidemic because the virusevolves so rapidly. Our researchis focused on HIV-1 evolution toanswer both basic and clinicalresearch questions about viraldynamics and development ofnew antiretroviral strategies.<strong>Clinic</strong>al Significance ofHIV-1 FitnessMultidrug-resistant (MDR)variants of HIV, with reducedsusceptibility to antiretroviralcompounds from two or more classesof drugs, are now commonly found in treated patients. Inthe absence of drug pressure, the most fit virus would beexpected to be the wild-type virus. But in the presence ofdrug-selective pressure, resistant virus is the most fit virus.However, despite the multitude of in vitro data, we still donot know how this relatively reduced viral fitness couldeventually affect the clinical outcome of patients withMDR virus. Using growth competition experiments andTaqMan ® real-time PCR technology, models of the impactof antiretroviral therapy on HIV-1 fitness and diseaseprogression are being developed.Anti-HIV-1 Mechanisms of CombinationTherapy with IFN-α and Protein TyrosinePhosphatase InhibitorsAlthough advances in HIV/AIDS therapeuticshave caused a decrease in both AIDS incidence anddeath in the U.S. and Europe, treatments withantiretroviral com-binations, host immune response,and vaccinations have all failed to control the HIV type 1(HIV-1) epidemic due to rapid evolution of the virus.Therefore, the need for therapeutic alternatives in thetreatment of HIV infec-tions has become clear.Interferons (IFNs) are part of the natural humandefensive response directed against virus infections,including HIV. Multiple studies have shown thatexogenous IFN type I inhibits HIV-1 replication in vitro.The Department of Molecular BiologyHIV: Fitness and Evolution StudiesLeading to New Antiretroviral TherapiesMiguel E. Quiñones-Mateu,Ph.D.<strong>Clinic</strong>al studies of exogenous IFNs taken alone or incombinations with antiretroviral drugs have shownsome success, especially for earlier HIV-1 primaryinfections. However, the role of IFNsin antiretroviral therapy and AIDSpathogenesis is still unknown. On theother hand, it has been reported thatinhibition of protein tyrosinephosphatases (PTPs, enzymes thatcontrol a diverse array of cellularproces-ses) by sodium stibogluconate(SSG, a drug used for the treatment ofleishmaniasis) enhances the in vitro signalingof IFN type I, perhaps increasingits antiviral effect. We are evaluatingthe in vitro and in vivo anti-HIV-1activity of IFN type I in combinationwith SSG and other PTP inhibitors, toboost the effects of IFNs in antiviraland/or immunotherapeutic treatments.Lethal Mutagenesis as a NewAntiretroviral TherapyTreatments with combinations of antiretroviralmedications do not completely inhibit HIV replication,eventually leading to treatment failure. Thus, there is asubstantial need for the availability of novel agents,which target different sites involved in the virus lifecycle. RNA viruses (such as HIV-1) replicate andevolve as complex mutant distributions termed viralquasi-species, which are powered by error-pronereplication and high mutation frequency. However,maintaining such a high mutation frequency isdangerous for the virus. An increase in the averageerror rate above a critical threshold during viralreplication should result in the loss of geneticinformation in a process that has been referred to asviolation of the error threshold or entry into errorcatastrophe. If an RNA virus quasi-species goesbeyond this mutation limit, the population will nolonger be viable. Interestingly, it has been pre-dictedthat RNA viruses’ high mutation frequencies are closeto this limit and can be forced into error catas-tropheby a moderate increase in mutation rate. This newconcept is opening new avenues for understanding viralinfections, and it should allow an assessment of thepossibilities of lethal mutagenesis as an antiviralstrategy against HIV.VIROLOGYTHE QUIÑONES-MATEU LABORATORYPOSTDOCTORAL FELLOWSJan Weber, Ph.D.Hector Rangel, Ph.D.RESEARCH TECHNICIANSBikram Chakraborty, B.S.Patti Kaiser, M.S.GRADUATE STUDENTMichael Marotta, B.S.COLLABORATORSEric J. Arts, Ph.D. 1Esteban Domingo, Ph.D. 2Jose A. Este, Ph.D. 3Michael M. Lederman, M.D. 1Miguel A. Martinez, Ph.D. 3Robert H. Silverman, Ph.D. 4Vicente Soriano, M.D. 5Cheryl A. Stoddart, Ph.D. 6Zahra Toossi, M.D. 1Guido Vanham, M.D., Ph.D. 7Taolin Yi, Ph.D. 41Case Western Reserve Univ.,<strong>Cleveland</strong>, OH2Centro de Biologia Molecular“Severo Ochoa,” UniversidadAutonoma deMadrid, Spain3Fundacio irsiCaixa, Barcelona,Spain4Dept. of Cancer Biology, CCF5Instituto de Salud Carlos III,Madrid, Spain6Gladstone Inst. of Virology andImmunology, Univ. of Californiaat San Francisco7Inst. of Tropical Medicine,Antwerp, BelgiumQuiñones-Mateu, M.E., Albright, J.L., Mas, A., Soriano, V., and E.J. Arts (1998) Analysis of pol gene heterogeneity, viral quasispecies, and drugresistance in individuals infected with group O strains of human immunodeficiency virus type 1. J. Virol. 72:9002-9015.Quiñones-Mateu, M.E., Ball, S.C., Marozsan, A.J., Torre, V.S., Albright, J.L., Vanham, G., van der Groen, G., Colebunders, R.L., and E.J. Arts(2000) A dual infection/competition assay shows a correlation between ex vivo HIV-1 fitness and disease progression. J. Virol. 74:9222-9233.Quiñones-Mateu, M.E., Gao, Y., Ball, S.C., Marozsan, A., Abraha, A., and E.J. Arts (2002) In vitro intersubtype recombinants of human immunodeficiencyvirus type 1: comparison to recent and circulating in vivo recombinant forms. J. Virol. 76:9600-9613.Quiñones-Mateu, M.E., Tadele, M., Parera, M., Mas, A., Weber, J., Rangel, H.R., Chakraborty, B., Clotet, B., Domingo, E., Menendez-Arias, L., andM.A. Martinez (2002) Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virustype 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J. Virol. 76:10546-10552.Ball, S.C., Abraha, A., Collins, K.R., Marozsan, A.J., Baird, H., Quiñones-Mateu, M.E., Penn-Nicholson, A., Murray, M., Richard, N., Lobritz, M.,Zimmerman, P.A., Kawamura, T., Blauvelt, A., and E.J. Arts (<strong>2003</strong>) Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virustype 1 isolates of subtypes B and C. J. Virol. 77:1021-1038.115